Sulphasalazine and Prednisone Compared with Sulphasalazine for Treating Active Crohn Disease

Mc, Rijk; Hogezand, van; Hj, van Lier; Jh, van Tongeren

doi:10.7326/0003-4819-114-6-445

Cited by 46 publications

(15 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These results were confirmed in other smaller studies [13, 14]. Details on these studies are provided above, in the SFS section.…”

Section: First-line Treatment Optionssupporting

confidence: 80%

“…Other smaller trials confirmed that SFS 3–6 g/day is superior to placebo in mild-to-moderate CD [11, 12]. In other well-designed studies, SFS showed no adjunctive effect on prednisone and no steroid-sparing effect [13], while prednisone has an adjunctive effect on SFS [14]. In one uncontrolled retrospective analysis, Goldstein et al [15 ]estimated that about 25% of patients with disease limited to the small bowel benefit from long-term SFS therapy.…”

Section: First-line Treatment Optionsmentioning

confidence: 70%

See 1 more Smart Citation

Mild-to-Moderate Active Luminal Crohn’s Disease

Michetti

Juillerat²,

Mottet³

et al. 2007

Digestion

View full text Add to dashboard Cite

The management of luminal Crohn’s disease, the most common form of initial presentation of the disease, depends on the location and the severity of the disease. Mild-to-moderate disease represents a relatively large proportion of patients with a first flare of luminal disease, which may also be associated with perianal disease. As quality of life of these patients inversely correlates with disease activity, adequate therapy is a central goal of the overall patient management. Treatment options include mainly sulfasalazine, budesonide and systemic steroids, while the role of mesalazine and antibiotics remains controversial. The role of biological therapies has not been thoroughly evaluated in patients with mild disease.

show abstract

“…These results were confirmed in other smaller studies [13, 14]. Details on these studies are provided above, in the SFS section.…”

Section: First-line Treatment Optionssupporting

confidence: 80%

Section: First-line Treatment Optionsmentioning

confidence: 70%

Mild-to-Moderate Active Luminal Crohn’s Disease

Michetti

Juillerat²,

Mottet³

et al. 2007

Digestion

View full text Add to dashboard Cite

show abstract

“…These results were confirmed in other smaller studies [12, 13]. Details about these studies are provided above, in the SFS section.…”

Section: First-line Treatment Optionssupporting

confidence: 80%

“…Other smaller trials have confirmed that SFS 3–6 g/day is superior to placebo in mild to moderate CD [10, 11]. In other well-designed studies, SFS showed no adjunctive effect on prednisone and no steroid-sparing effect [12], while prednisone has an adjunctive effect on SFS [13]. In one uncontrolled retrospective analysis, Goldstein et al [14] estimated that about 25% of patients with disease limited to the small bowel benefit from long-term SFS therapy.…”

Section: First-line Treatment Optionsmentioning

confidence: 99%

Therapy of Mild to Moderate Luminal Crohn’s Disease

et al. 2005

View full text Add to dashboard Cite

The management of luminal Crohn’s disease, the most common form of initial presentation of the disease, depends on the location and the severity of the lesions. Mild to moderate disease represents a relatively large proportion of patients with a first flare of luminal disease, which may also be associated with perianal disease. As quality of life of these patients correlates with disease activity, adequate therapy is a central goal of the overall patient management. Treatment options include mainly sulfasalazine, budesonide and systemic steroids, while the role of mesalazine and antibiotics remains controversial. The role of biological therapies in mild to moderate disease has not been thoroughly evaluated and will not be discussed here.

show abstract

“…ere are no short-or long-term bene ts from the addition of aminosalicylates to corticosteroids (92,125,126) . Azathioprine and 6-mercaptopurine have had demonstrable adjunctive bene ts to steroids in adults (number needed to treat (NNT) = 5) (127,128) .…”

Section: Mild To Moderate Active Diseasementioning

confidence: 99%

Management of Crohn's Disease in Adults

2009

View full text Add to dashboard Cite

Guidelines for clinical practice are intended to suggest preferable approaches to particular medical problems as established by interpretation and collation of scientifi cally valid research, derived from extensive review of published literature. When data that will withstand objective scrutiny are not available, a recommendation may be made based on a consensus of experts. Guidelines are intended to apply to the clinical situation for all physicians without regard to specialty. Guidelines are intended to be fl exible, not necessarily indicating the only acceptable approach, and should be distinguished from standards of care that are infl exible and rarely violated. Given the wide range of choices in any health-care problem, the physician should select the course best suited to the individual patient and the clinical situation presented. These guidelines are developed under the auspices of the American College of Gastroenterology and its Practice Parameters Committee. Expert opinion is solicited from the outset for the document. The quality of evidence upon which a specifi c recommendation is based is as follows: Grade A: Homogeneous evidence from multiple well-designed randomized (therapeutic) or cohort (descriptive) controlled trials, each involving a number of participants to be of suffi cient statistical power. Grade B: Evidence from at least one large well-designed clinical trial with or without randomization, from cohort or case -control analytic studies, or well-designed meta-analysis. Grade C: Evidence based on clinical experience, descriptive studies, or reports of expert committees. The Committee reviews guidelines in depth, with participation from experienced clinicians and others in related fi elds. The fi nal recommendations are based on the data available at the time of the production of the document and may be updated with pertinent scientifi c developments at a later time.

show abstract

Sulphasalazine and Prednisone Compared with Sulphasalazine for Treating Active Crohn Disease

Abstract: The use of prednisone in addition to sulphasalazine in patients with active Crohn disease results in a significantly faster initial improvement, but not in a significantly better result after 16 weeks of treatment, when disease activity is measured by the Van Hees Activity Index.

Cited by 46 publications

References 8 publications

Mild-to-Moderate Active Luminal Crohn’s Disease

Mild-to-Moderate Active Luminal Crohn’s Disease

Therapy of Mild to Moderate Luminal Crohn’s Disease

Management of Crohn's Disease in Adults

Contact Info

Product

Resources

About